For the 71 patients with crizotinib-pretreated ALK+ NSCLC, the KM-estimated median PFS was 13.4 months (95% CI: 9.2–16.7), with event-free rates of 19% (95% CI: 10–29) at 3 years and 10% (95% CI: 4–20) at 5 years (Table 1). The gene discussed is ALK; the disease is non-small cell lung carcinoma.